Nasal septum perforation and bevacizumab

ISSN： 1357-0560

Source： Medical Oncology, Vol.28, Iss.1, 2011-03, pp. : 89-93

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer

By Petrelli Fausto

Breast Cancer, Vol. 18, Iss. 3, 2011-07 ,pp. : 226-230

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab-induced nasal septal perforation: Incidence of symptomatic, confirmed event(s) in colorectal cancer patients

By Ramiscal Judi Anne B. Jatoi Aminah

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 578-581

Informa Healthcare

Access to resources Recommend Favorite

Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer

By Saif Muhammad Elfiky Aymen Salem Ronald

Annals of Surgical Oncology, Vol. 14, Iss. 6, 2007-06 ,pp. : 1860-1869

Springer Publishing Company

Access to resources Recommend Favorite

First description of an uterine perforation potentially imputable to treatment with bevacizumab

By Uguen Thomas Leconte Bérengère Desgrippes Romain Tchoundeu Belinda Bretagne Jean François Manfredi Sylvain

Acta Oncologica, Vol. 51, Iss. 8, 2012-11 ,pp. : 1102-1104

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab (Avastin®)

By Shimoyama Tatsu

Japanese Journal of Cancer and Chemotherapy, Vol. 36, Iss. 3, 2009-03 ,pp. : 523-530

Sunmedia

Access to resources Recommend Favorite